Daraxonrasib Triples Pancreatic Cancer Survival

0:00It's April 13th. You're listening to Tampa Bay News today, AI-powered local news. I'm Corey with the story. Revolution medicines announce breakthrough results from a phase 3 trial on their drug, Diracson Resib, for advanced pancreatic cancer. Patients on this once daily pill survive the median of 13.2 months, nearly doubling the 6.7 months from standard chemo. The treatment was well tolerated with no major new safety issues. This drug targets RES mutations, which drive over 90% of pancreatic cancers and make the disease super-aggressive. The trial included folks with various RES types and even some without identified mutations, checking both progression-free and overall survival across. The board. Experts are calling it a game changer. Brian Wolpen from Harvard says new options like this are desperately needed to extend lives and boost quality for patients who've already progressed. In chemo, it's a real step forward in a field where survival rates have lagged behind.

1:03The company confirmed these interim results are final. They're gearing up to submit data to regulators by the Food and Drug Administration worldwide. With pancreatic cancer still hitting hard, Diracson Resib could open doors for targeted therapy, giving patients more time and hope in the fight. Stay tuned for those approval updates.